TuHURA Biosciences draws $650,000 more under Parkview credit line

TuHURA Biosciences, Inc. disclosed in an 8-K filed for an October 9, 2026 event that it had taken another draw on its revolving credit facility. On October 9, 2026, the Company received and borrowed an additional draw under the revolving credit facility in the amount $650,000 and expects to use the funds for general corporate purposes.¹

The facility itself dates back to earlier in the year. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. entered into a Loan Agreement with Parkview Holdings One LLC, acting as lender.¹ Under its terms, the agreement allows for a revolving credit line running through maturity on April 21, 2031, capped at a total borrowing limit of $50 million.¹

For full terms of the arrangement, the company pointed to the original loan document. It noted that the summary in the filing is not exhaustive and should be read alongside the full agreement, which was attached as an exhibit to the 8-K the company filed on April 22, 2026.¹

The filing's forward-looking statements section flagged risks tied to the arrangement, including whether TuHURA can meet the conditions needed to draw further funds or stay in compliance with the loan terms, whether the amounts available under the facility will be enough to cover its planned operations and development work, and potential conflicts of interest since the lender is described as an affiliate of the Company’s largest stockholder.¹

The report was signed on October 16, 2026 by Chief Financial Officer Dan Dearborn. Date: October 16, 2026 By: /s/ Dan Dearborn Name: Dan Dearborn Title: Chief Financial Officer¹